{"title":"更正“美国2型糖尿病患者基础胰岛素滴定的观点和经验:一项横断面调查”","authors":"","doi":"10.1111/dom.15253","DOIUrl":null,"url":null,"abstract":"<p>Harris SB, Mohammedi K, Bertolini M, et al. Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey. Diabetes Obes Metab. 2023; 25(5): 1408–1412. doi:10.1111/dom.14973.</p><p>In the article “Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey”, Figure 1E, extremely confident is 27% when it should be 19%. There are no errors in the text. Please refer to the corrected Figure 1 below:</p><p>The supporting information has also been updated online.</p><p>We apologize for any inconvenience caused.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"25 11","pages":"3430-3431"},"PeriodicalIF":5.4000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.15253","citationCount":"0","resultStr":"{\"title\":\"Correction to “Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey”\",\"authors\":\"\",\"doi\":\"10.1111/dom.15253\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Harris SB, Mohammedi K, Bertolini M, et al. Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey. Diabetes Obes Metab. 2023; 25(5): 1408–1412. doi:10.1111/dom.14973.</p><p>In the article “Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey”, Figure 1E, extremely confident is 27% when it should be 19%. There are no errors in the text. Please refer to the corrected Figure 1 below:</p><p>The supporting information has also been updated online.</p><p>We apologize for any inconvenience caused.</p>\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\"25 11\",\"pages\":\"3430-3431\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2023-08-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.15253\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/dom.15253\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dom.15253","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Correction to “Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey”
Harris SB, Mohammedi K, Bertolini M, et al. Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey. Diabetes Obes Metab. 2023; 25(5): 1408–1412. doi:10.1111/dom.14973.
In the article “Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey”, Figure 1E, extremely confident is 27% when it should be 19%. There are no errors in the text. Please refer to the corrected Figure 1 below:
The supporting information has also been updated online.
期刊介绍:
Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.